<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230111057113N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-01-03</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Examination of the second sample of ejaculated sperm in patients with high DNA fragmentation( DFI)</public_title>
      <acronym>TESE</acronym>
      <scientific_title>Fertilization rate comparison in IntraCytoplasmic Sperm Injection(ICSI) cycles with second ejaculated sperm sample versus(Testicular sperm extraction) TESE sample in patients with high Deoxyribonucleic acid (DNA) fragmentation index(high DFI)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69352</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: patients are randomly placed in one of the two study and intervention groups with the help of a random number table and receive the services related to the same group.</study_design>
      <phase>2</phase>
      <hc_freetext>High DNA fragmentation index in sperm of infertile men.</hc_freetext>
      <i_freetext>Intervention 1: Control group: TESE sample (TESE sample is prepared from patients under anesthesia). Intervention 2: Intervention group: second sample of ejaculated sperm (patients will be asked to take another sample from the first sample within one to three hours).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only a part of the data, such as the information related to the main result or the like, can be shared.

When:
The access period starts 6 months after the results are published

To whom:
The data will be available only to researchers working in academic and scientific institutions

Conditions:
It is allowed to use the documents for the thesis with references

Where to obtain:
Email to this address
dresmaeili@gmail.com

How to obtain:
After a month, they will receive the results

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>samaneh esmaeili</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Taleghani Hosp,Araabi st,Yaman Ave,Chamran,Tehran Highway,</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985711151</zip>
        <telephone>+98 21 2303 1307</telephone>
        <email>dresmaeili@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>samaneh esmaeili</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Taleghani Hosp,Araabi st,Yaman Ave,Chamran,Tehran Highway,</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>Taleghani Hosp,Araab</zip>
        <telephone>+98 21 2303 1307</telephone>
        <email>dresmaeili@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>At least 1 failed ART(Assissted Reproductive technology) attempts
women between 18 and 40 years old
High DFI levels of more than 30% in semen samples at admission
Men  between 20and 50 years old</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>A male patient with obvious abnormalities noted in the medical history, physical examination, endocrine profile, and evidence of subclinical genital infections, leukocytospermia, cryptorchidism, cancer, history of chemotherapy or radiotherapy, or severe varicocele
2- Women with a history of poor response to ovarian stimulation or meeting the POSEIDON((Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number) criteria for expected poor responders
Pre-implantation genetic screening (PGS), frozen/thawed embryo transfer cycles,
Apparent pathology of the uterus or tube
5- People with genetic disorders
6- Male patients with heavy smoking (more than 20 cigarettes per day)
7-Severe endometriosis
8-Patients with sperm freezing</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N46.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other male infertility</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: TESE sample (TESE sample is prepared from patients under anesthesia)</i_keyword>
      <i_keyword>Intervention group: second sample of ejaculated sperm (patients will be asked to take another sample from the first sample within one to three hours)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Fertilization rate determination in ICSI (IntraCytoplasmic Sperm  Injection)cycles with the second sample of ejaculated sperm in patients with high DFI(DNA Fragmentation Index). Timepoint: Checking the fertilization rate after 3 days following oocyte injection. Method of measurement: percentage (calculated by dividing the number of 2 pronuclei by the total number of injected eggs).</prim_outcome>
      <prim_outcome>Determining the amount of grade one and two embryos in ICSI cycles with the second sample of ejaculated sperm in patients with high DFI. Timepoint: The number of grade 1 and 2 embryos on day 3 after injection. Method of measurement: Percentage (calculated by dividing the number of grade one and two embryos by the total number of embryos formed).</prim_outcome>
      <prim_outcome>Determination of grade one and two embryos in ICSI cycles with TESE (Testicular Sperm Extraction)samples in patients with high DFI. Timepoint: The number of grade 1 and 2 embryos on day 3  after injection. Method of measurement: Percentage (calculated by dividing the number of grade one and two embryos by the total number of embryos formed).</prim_outcome>
      <prim_outcome>Fertilization rate determination in ICSI cycles with TESE-derived sperm(Testicular Sperm extraction) in patients with high DFI. Timepoint: Checking the fertilization rate after 3 days following oocyte injection. Method of measurement: percentage (calculated by dividing the number of pronuclei by the total number of injected eggs).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Investigating the forward motility of sperms in the second sample of ejaculated sperm. Timepoint: The sample within one hour of the first sample. Method of measurement: The percentage of forward-moving spermatozoa to the total spermatozoa observed by light microscopy.</sec_outcome>
      <sec_outcome>Examination of other sperm parameters in TESE (Testicular sperm Extraction)sample. Timepoint: Sample immediately after TESE. Method of measurement: The percentage of forward-moving spermatozoa to the total spermatozoa observed by light microscopy.</sec_outcome>
      <sec_outcome>Examination of sperms with normal shape in the second sperm sample. Timepoint: Sample within one to three hours of the first sample. Method of measurement: The percentage of sperms with normal shape to the total sperms with a light microscope.</sec_outcome>
      <sec_outcome>Examination of sperms with normal shape in the sample obtained from TESE. Timepoint: Sample immediately after TESE. Method of measurement: The percentage of sperms with normal shape to the total sperms and observed with a light microscope.</sec_outcome>
      <sec_outcome>Examining the concentration of sperms in the second sample of ejaculated sperm. Timepoint: The sample within one hour  to three after  the first sample. Method of measurement: Calculate it under a light microscope and in one cc of ejaculate.</sec_outcome>
      <sec_outcome>Investigating the concentration of sperms in the TESE sample. Timepoint: Sample immediately after TESE. Method of measurement: Calculate it under a light microscope and in a cc of semen sample.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-12-13</approval_date>
        <contact_name>Ethics Committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Taleghani Hosp,Araabi st,Yaman Ave,Chamran,Tehran Highway, Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
